HomeCompareGSSRF vs ABBV

GSSRF vs ABBV: Dividend Comparison 2026

GSSRF yields 11111.11% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GSSRF wins by $155845322245618304.00M in total portfolio value
10 years
GSSRF
GSSRF
● Live price
11111.11%
Share price
$0.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$155845322245618304.00M
Annual income
$153,134,179,268,263,440,000,000.00
Full GSSRF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — GSSRF vs ABBV

📍 GSSRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGSSRFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GSSRF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GSSRF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GSSRF
Annual income on $10K today (after 15% tax)
$944,444.44/yr
After 10yr DRIP, annual income (after tax)
$130,164,052,378,023,920,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, GSSRF beats the other by $130,164,052,378,023,920,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GSSRF + ABBV for your $10,000?

GSSRF: 50%ABBV: 50%
100% ABBV50/50100% GSSRF
Portfolio after 10yr
$77922661122809152.00M
Annual income
$76,567,089,634,131,720,000,000.00/yr
Blended yield
98.26%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

GSSRF
No analyst data
Altman Z
-35.8
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GSSRF buys
0
ABBV buys
0
No recent congressional trades found for GSSRF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGSSRFABBV
Forward yield11111.11%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$155845322245618304.00M$102.3K
Annual income after 10y$153,134,179,268,263,440,000,000.00$24,771.77
Total dividends collected$155665220770885760.00M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GSSRF vs ABBV ($10,000, DRIP)

YearGSSRF PortfolioGSSRF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$1,121,811$1,111,111.11$11,550$430.00+$1.11MGSSRF
2$117,691,627$116,491,288.80$13,472$627.96+$117.68MGSSRF
3$11,547,755,012$11,421,824,971.17$15,906$926.08+$11547.74MGSSRF
4$1,059,734,753,299$1,047,378,655,436.53$19,071$1,382.55+$1059734.73MGSSRF
5$90,963,535,000,723$89,829,618,814,692.62$23,302$2,095.81+$90963534.98MGSSRF
6$7,303,524,681,616,793$7,206,193,699,166,020.00$29,150$3,237.93+$7303524681.59MGSSRF
7$548,553,313,414,587,650$540,738,542,005,257,700.00$37,536$5,121.41+$548553313414.55MGSSRF
8$38,543,778,083,006,005,000$37,956,826,037,652,400,000.00$50,079$8,338.38+$38543778083005.95MGSSRF
9$2,533,778,483,509,246,600,000$2,492,536,640,960,430,300,000.00$69,753$14,065.80+$2533778483509246.50MGSSRF
10$155,845,322,245,618,300,000,000$153,134,179,268,263,440,000,000.00$102,337$24,771.77+$155845322245618304.00MGSSRF

GSSRF vs ABBV: Complete Analysis 2026

GSSRFStock

Gossan Resources Limited, an exploration and evaluation stage company, engages in the acquisition, exploration, and development of resource properties in Canada. It holds interest in the Glitter property located in the sturgeon lake greenstone belt of northwestern Ontario; the Gander Gold property covers an area of 8,875 hectares situated in Newfoundland; and the Weir Pond project covers an area of 975 hectares and the Island Pond properties cover an area of 1,050 hectares located in Newfoundland. The company also owns interests in a portfolio of properties hosting gold, platinum group, and base metals, as well as specialty green battery metals, vanadium, titanium, tantalum, lithium, dolomite, and chromium. In addition, it holds production royalty interests in a high-purity silica sand deposit. Gossan Resources Limited was incorporated in 1980 and is headquartered in Winnipeg, Canada.

Full GSSRF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this GSSRF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GSSRF vs SCHDGSSRF vs JEPIGSSRF vs OGSSRF vs KOGSSRF vs MAINGSSRF vs JNJGSSRF vs MRKGSSRF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.